CT 37
Alternative Names: CT-37Latest Information Update: 21 Jan 2026
At a glance
- Originator Stromatis Pharma
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Apr 2025 Preclinical trials in Cancer in USA (Parenteral) (Stromatis Pharma pipeline, April 2025)